EI report of Tongliao Meihua's isoleucine project published

Publish time: 23rd April, 2024      Source: CCM
Information collection and data processing:  CCM     For more information, please contact us

    Summary: Tongliao Meihua plans to introduce 6,500 t/a of production capacity for isoleucine.   


    On 22 March, the environmental impact (EI) report of isoleucine project from Tongliao Meihua Biological Sci-tech Co., Ltd. (Tongliao Meihua) was published.   


    Project overview   

  •     Type of project: reconstruction and expansion   
  •     Investment amount: USD3.80 million (RMB27.00 million), 4.81% of which (USD182,946/RMB1.30 million) will be for environmental protection purposes   
  •     Construction site location: Horqin District, Tongliao City, Inner Mongolia Autonomous Region   
  •     Site area: 4,988 square metres   
  •     Construction details: In the existing tryptophan production workshop, the tryptophan line will be dismantled, and a new isoleucine line will be built.   
  •     Planned capacities: 6,450 t/a for feed-grade isoleucine and 50 t/a for food-grade isoleucine   
  •     Major raw materials needed in production: 5,854 t/a of glucose and 3,089 t/a of beet molasses   
  •     Production process: The microbial anaerobic fermentation method is first applied to produce fermentation broth. Then, fermentation broth undergoes filtration by ceramic membrane, decolourisation by activated carbon, multiple-effect evaporation, crystallisation, separation and drying. In the end, isoleucine is produced.   
  •     Labour needs & working schedule: There won't be new job posts created for this project. There will be 333 working days/7,992 working hours per year.   
  •     Economic benefits: Estimations show the project will bring in yearly operating revenues of USD54.88 million (RMB390.00 million) and yearly after-tax profits of USD20.94 million (RMB148.77 million) after it reaches full operation.   

        Tongliao Meihua's operating revenue for 2023 totalled USD1.41 billion (RMB10.02 billion) and net profit for 2023 was USD142.14 million (RMB1.01 billion), according to the performance report of its parent Meihua Holdings Group Co., Ltd. (stock code: 600873.SH). Tongliao Meihua's production capacities for amino acids, including the operational ones and the ones to be built, are summarised in the following table.   

      Table Tongliao Meihua's production capacities for amino acids in its factory compound
                Product                        Production capacity, t/a                        Note           
                Gourmet powder monosodium glutamate                        200,000                        In operation           
                500,000                        To be built; related project has been filed for record           
                Tryptophan                        10,000                        In operation; to be removed in order to make way for isoleucine project           
                Glutamine                        5,000                        In operation           
                Valine                        21,800           
                Threonine                        250,000           
                Isoleucine                        6,500                        To be built by isoleucine project           

    Source: Tongliao Meihua



      More information can be found at CCM Amino acid China Monthly Report.


    About CCM:

    CCM is the leading market
    intelligence provider for China's agriculture, chemicals, food & feed and life science markets. Founded in 2001, CCM offers a range of content solutions, from price and trade analysis to industry newsletters and customized market research reports. CCM is a brand of Kcomber Inc.

    For more information about CCM, please visit www.cnchemicals.com or get in touch with us directly by emailing econtact@cnchemicals.com or calling +86-20-37616606.